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mTORC1-independent TFEB activation via Akt
inhibition promotes cellular clearance
in neurodegenerative storage diseases
Michela Palmieri1, Rituraj Pal2,*, Hemanth R. Nelvagal3,*, Parisa Lotﬁ1, Gary R. Stinnett2, Michelle L. Seymour4,
Arindam Chaudhury5, Lakshya Bajaj1, Vitaliy V Bondar1, Laura Bremner3, Usama Saleem3, Dennis Y. Tse6,7,
Deepthi Sanagasetti1, Samuel M. Wu6, Joel R. Neilson5, Fred A. Pereira4, Robia G. Pautler2, George G. Rodney2,8,
Jonathan D. Cooper3 & Marco Sardiello1
Neurodegenerative diseases characterized by aberrant accumulation of undigested cellular
components represent unmet medical conditions for which the identiﬁcation of actionable
targets is urgently needed. Here we identify a pharmacologically actionable pathway that
controls cellular clearance via Akt modulation of transcription factor EB (TFEB), a master
regulator of lysosomal pathways. We show that Akt phosphorylates TFEB at Ser467 and
represses TFEB nuclear translocation independently of mechanistic target of rapamycin
complex 1 (mTORC1), a known TFEB inhibitor. The autophagy enhancer trehalose activates
TFEB by diminishing Akt activity. Administration of trehalose to a mouse model of Batten
disease, a prototypical neurodegenerative disease presenting with intralysosomal storage,
enhances clearance of proteolipid aggregates, reduces neuropathology and prolongs survival
of diseased mice. Pharmacological inhibition of Akt promotes cellular clearance in cells from
patients with a variety of lysosomal diseases, thus suggesting broad applicability of this
approach. These ﬁndings open new perspectives for the clinical translation of TFEB-mediated
enhancement of cellular clearance in neurodegenerative storage diseases.
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N
eurodegenerative diseases pose a major burden on public
health that is expected to increase in the next decades due
to the extension of life expectancy and global population
aging. Unlike other human health conditions, neurodegenerative
diseases have proven to be extraordinarily refractory to attempts
to halt or slow their progression. Indeed, no approved treatments
exist for any neurodegenerative disease that signiﬁcantly
extend life span or modify clinical progression1. Therefore,
neurodegenerative diseases represent unmet medical conditions
for which the identiﬁcation of effective, pharmacologically
actionable targets is urgently needed.
Mounting genetic and experimental evidence converges on
cellular clearance pathways as the main processes implicated in
the pathogenesis of neurodegenerative diseases. Indeed, the vast
majority of patients with a neurodegenerative condition have
aberrant neuronal accumulation of undigested macromolecules,
as a result of an overwhelmed or impaired cellular degradative
system2,3. Among the identiﬁed causes is the abnormal
generation of aggregation-prone proteins, which are less
efﬁciently disposed of by the cell, and genetic defects that
directly or indirectly affect the autophagic–lysosomal degradative
pathway4. Hence, a general paradigm is emerging, which
proposes that enhancement of cellular clearance in these disease
conditions will help maintain cellular homoeostasis and prevent
neuronal cell death5,6. Our recent identiﬁcation of a genetic
program that oversees lysosomal biogenesis and function has
provided a suitable target to manipulate lysosomal degradative
pathways7. The basic helix-loop-helix transcription factor EB
(TFEB) indeed acts as a master regulator of cellular clearance
through the enhancement of several processes that include
lysosomal proliferation8, expression of degradative enzymes8,9,
autophagy10, lysosomal exocytosis11 and lysosomal proteostasis12.
In vivo studies based on heterologous expression of TFEB have
shown improved clearance and amelioration of disease
phenotypes in rodent models of neurodegenerative disorders
such as Alzheimer’s disease13,14, tauopathy15, Parkinson’s
disease16 and Huntington’s disease8,17. An opportunity for
pharmacological activation of TFEB has stemmed from cell-
based studies that indicate that TFEB is negatively regulated by
the mechanistic target of rapamycin complex 1 (mTORC1)18–20,
the main known factor restricting autophagy induction. Catalytic
inhibition of mTORC1 in cells leads to TFEB activation; however,
rapamycin—the mTORC1 allosteric inhibitor that along with its
analogues is leading research in mTOR-related translational
applications—is quite ineffective at activating TFEB18–20. Indeed,
no pharmacological therapy of TFEB activation has been
proposed yet. The identiﬁcation of alternative routes to activate
TFEB is therefore needed to move the ﬁeld forward in
translational applications.
Here we identify the serine/threonine kinase Akt (protein
kinase B) as a pharmacologically actionable target that controls
TFEB activity independently of mTORC1. We ﬁnd that the
non-reducing disaccharide of glucose, a-D-glucopyranosyl
a-D-glucopyranoside or trehalose, an mTOR-independent
autophagy inducer21, promotes nuclear translocation of
TFEB by inhibiting Akt. We show that trehalose administration
reduces disease burden in a mouse model of a prototypical
neurodegenerative disease that presents with abnormal intra-
lysosomal accumulation of undegraded proteinaceous material.
We demonstrate that TFEB activity is modulated by Akt
phosphorylation at Ser467, and that Akt pharmacological
inhibition promotes cellular clearance in a variety of models of
genetic diseases presenting with impairment of lysosomal
pathways. Modulation of Akt activity is the subject of
intense clinical studies. Therefore, the ﬁnding that Akt controls
TFEB-mediated clearance opens novel perspectives for
future pharmacological therapies of neurodegenerative storage
disorders.
Results
Trehalose attenuates neuropathology in a model of JNCL. The
most documented example of mTORC1-independent activation
of cellular clearance is that exerted by trehalose22–26. We
hypothesized that trehalose activates TFEB through a hitherto
uncharacterized pathway, and set out to test this hypothesis
using a prototypical model of aberrant intralysosomal storage
represented by juvenile neuronal ceroid lipofuscinosis (JNCL
or Batten disease; OMIM #204200), the most prevalent
neurodegenerative disorder of childhood. JNCL is caused
by mutations in CLN3, a gene involved in the regulation
of lysosomal homoeostasis27–29, and is characterized by
autophagic impairment and intralysosomal accumulation of
ceroid lipopigment, which is detectable by confocal and
electron microscopy30,31.
Oral trehalose administration to Cln3Dex7-8 mice, an estab-
lished model of JNCL32, signiﬁcantly extended their life span.
The median survival of Cln3Dex7-8 mice increased from 454 to
522 days (15% increase, log-rank P¼ 0.00566) and the maximum
life span increased from 544 to 699 days (28% increase; Fig. 1a).
Post mortem examination and neuroimaging studies of
JNCL patients have shown generalized brain atrophy,
including signiﬁcant thinning of the corpus callosum (CC) and
brainstem33,34. Magnetic resonance imaging (MRI) studies in
JNCL mice reported that CLN3 protein deﬁciency results in a
similar generalized atrophy of the brain, thereby mirroring the
human condition35. We measured the wet brain weight of
12-month-old Cln3Dex7-8 mice (0.355±0.024 g) and found that it
was indeed signiﬁcantly lower than that of age-matched wild-type
(WT) mice (0.516±0.021 g; P¼ 0.0016); however, this difference
was largely rescued by trehalose treatment (0.473±0.028 g;
difference with untreated Cln3Dex7-8 mice, P¼ 0.032; Fig. 1b).
In contrast, trehalose administration did not affect the body
weight of Cln3Dex7-8 or WT mice (Supplementary Fig. 1). We
next evaluated the CC volume of ﬁxed brains by MRI analysis.
Quantitative measurement of 48 stacks per sample showed that
Cln3Dex7-8 mice had a marked reduction in the volume of the
CC (12.96±0.43mm3; Supplementary Movie 1) compared
with their WT counterparts (16.81±0.89mm3; P¼ 0.0081;
Fig. 1c; Supplementary Movie 2), which was also rescued by
the treatment (15.02±0.33mm3; difference with untreated
Cln3Dex7-8 mice, P¼ 0.027; Fig. 1c; Supplementary Movie 3).
The analysis of WT mice treated with trehalose did not show any
signiﬁcant changes in CC volume (18.27±0.66mm3; Fig. 1c;
Supplementary Movie 4).
Six-month-old Cln3Dex7-8 mice exhibited reduced pain sensi-
tivity in a hot plate assay, which was fully restored by trehalose
(Fig. 1d). Auditory brainstem response (ABR) analysis in
10-month-old mice showed that Cln3Dex7-8 mice have elevations
in ABR thresholds relative to WT mice (P¼ 0.01027), indicating
low-frequency hearing loss (Supplementary Fig. 2). Trehalose
treatment resulted in lower ABR thresholds in both genotypes
compared with untreated age-matched controls, indicating
protection of auditory function (Supplementary Fig. 2). We also
attempted to evaluate retinal function by performing electro-
retinogram analysis of 11-month-old mice; however, several
untreated WT mice showed poor response to the test, indicating
severe vision loss. The genetic background of our mouse colony
(CD-1) had been previously associated with inherited retinal
degeneration inB60% of males and other phenotypes decreasing
vision36,37. Thus, an evaluation of treatment-associated changes
in electroretinogram could not be performed.
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We next performed microscopic analysis of the brains of
Cln3Dex7-8 mice to ascertain whether trehalose modiﬁes the
accumulation of ceroid lipopigments. We focused on the primary
somatosensory barrel ﬁeld cortex (S1BF) and on the thalamic
ventral posterior medial and lateral nuclei (VPM/VPL), which
relays sensory information to the S1BF, because—differently from
other regions of the brain—both structures are consistently and
severely affected in mouse models of Batten disease38. Both
regions from 7- and 12-month-old Cln3Dex7-8mice displayed a
strong presence of punctate autoﬂuorescent material compared to
WT mice, which was found to be signiﬁcantly reduced by
trehalose treatment at both time points (Fig. 2a–d). Transmission
electron microscopy (TEM) analysis of Cln3Dex7-8 mouse brains
conﬁrmed marked accumulation of electron-dense cytoplasmic
material in both Purkinje cells and cortical neurons (Fig. 2e,f).
Higher magniﬁcation revealed that such electron-dense material
consists of the characteristic ﬁngerprint proﬁle structures
(Supplementary Fig. 3) previously associated with both
human and mouse JNCL pathology31,32. Trehalose treatment
signiﬁcantly reduced the number of ﬁngerprint proﬁles in
Purkinje cells (P¼ 0.047) and cortical neurons (P¼ 0.017;
Fig. 2e,f), conﬁrming enhancement of cellular clearance in
neurons. We next evaluated the effect of trehalose on
inﬂammation. Previous studies reported reactive gliosis and
microglial activation in VPM/VPL and S1BF regions of Cln3Dex7-8
mice38. Stereological analyses showed that 7-month-old Cln3Dex7-8
mice had a marked increase in GFAP and CD68 immunoreactivity
in these brain regions compared to age-matched WT mice, thus
conﬁrming reactive gliosis and microglial activation (Fig. 3a–d).
Both astrocytosis and activation of microglia were exacerbated at
12 months of age (Fig. 3e–h). This progressive neuroinﬂammation
was mitigated by trehalose administration (Fig. 3a,c,e,f,h).
Taken together, our data show that treatment with an
mTORC1-independent enhancer of clearance reduces brain
atrophy, accumulation of lipopigments, and neuroinﬂammation
in a model of a prototypical storage disorder caused by primary
impairment of the lysosomal system.
Trehalose activates TFEB independently of mTORC1. The
observed reduction of storage material in Cln3Dex7-8 mice sug-
gests that trehalose enhances lysosomal function. TFEB regulates
the expression of lysosomal genes by directly binding to the
‘coordinated lysosomal expression and regulation’ (CLEAR) sites
that are present at their promoters8. To test whether trehalose
induces nuclear translocation of TFEB—a hallmark of TFEB
activation—we examined cells stably expressing TFEB-3xFLAG
(HeLa/TFEB)8. Confocal microscopy showed progressive TFEB
nuclear translocation on trehalose administration within 24 h
(Fig. 4a). Quantiﬁcation analysis revealed that, in this time frame,
cells with nuclear TFEB increased from 20 to 480% (Fig. 4b).
Recent reports have demonstrated that mTORC1 phosphorylates
TFEB, thereby promoting TFEB cytosolic retention18–20.
To mechanistically test whether trehalose activates TFEB
through an mTORC1-independent pathway, we used two
models of constitutive activation of mTORC1. The ﬁrst model
is represented by cells that are null for the tuberous sclerosis
complex 2 gene, Tsc2 (Tsc2 / )39. TSC2 forms a heterodimeric
complex with TSC1 that suppresses mTORC1 activity; loss of
either TSC2 or TSC1 therefore leads to constitutive mTORC1
activation40. Western blot and confocal microscopy analysis
of Tsc2 / mouse embryonic ﬁbroblasts and control mouse
embryonic ﬁbroblasts showed that, unlike the mTORC1
inhibitors (rapamycin and Torin 1), trehalose does not alter
mTORC1 signalling (Fig. 4c; Supplementary Fig. 4) and does not
modify phosphorylation of TFEB S211 (an mTORC1 target
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Figure 1 | Amelioration of disease pathology in JNCL mice fed with trehalose. (a) Trehalose signiﬁcantly extended survival of Cln3Dex7–8 mice. Treated
(Tre) Cln3Dex7-8 mice: n¼ 13. Untreated (UT) Cln3Dex7-8 mice: n¼ 12. (b) Weight of brains from 12-month-old WT and Cln3Dex7-8 mice with or without
trehalose treatment. All groups of mice, n¼4 or 5. (c) Fractional anisotropy of brains from 12-month-old WTand Cln3Dex7-8 mice with or without trehalose
treatment. Left panel: representative coronal images of the four groups of brains; corpus callosa are indicated by the yellow arrowhead. Right panel:
quantiﬁcation of callosal volume. All groups of mice, n¼ 3 or 4. Scale bar, 2 mm. Three-dimensional reconstructions of the corpus callosum in mice from
treated and control groups are reported in Supplementary Movies 1–4. (d) In the hot plate test, Cln3Dex7-8 mice respond slower when placed on a 50 C
heated metal surface compared with wild-type (WT) littermates, indicating reduced pain sensitivity. Trehalose (Tre) treatment rescued this phenotype in
Cln3Dex7-8 mice. All groups of mice, n¼ 14–19. Data represent means±s.e.m. *Po0.05, **Po0.01, ***Po0.001.
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site)18,19 (Supplementary Fig. 5), but does induce TFEB nuclear
translocation even with an active mTORC1 (Fig. 4d,e). The
second model we used was obtained with a construct carrying the
E2419K amino-acid substitution in the mTOR kinase domain,
which results in a constitutively active mTOR (mTORE2419K)41.
Confocal microscopic analysis showed that trehalose treatment
induces nuclear translocation of TFEB in cells transfected with
WT mTOR or mTORE2419K (Fig. 4f,g). Together, these data
indicate that trehalose signalling overrides mTORC1 control of
TFEB localization. Short interfering RNA (siRNA)-mediated
depletion of the mTORC2-speciﬁc component RICTOR did not
affect TFEB subcellular localization in the presence or absence of
trehalose (Supplementary Fig. 6a,b), in agreement with previous
studies showing that mTORC2 does not modulate TFEB nuclear
translocation18.
We then asked whether trehalose activation of TFEB exerts
transcriptional effects that are speciﬁc to the CLEAR network,
or whether trehalose activates additional programs that might
be independent of TFEB. To address this question, we ﬁrst
conﬁrmed that trehalose activates the CLEAR network in human
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Figure 2 | Assessment of storage burden. (a,b) Confocal images and quantiﬁcation of the storage material in trehalose-treated (Tre) and untreated mice
in the primary somatosensory cortex (S1BF; a), and in the interconnected thalamic relay nucleus (VPM/VPL; b) at 7 month of age. Thresholding image
analysis revealed higher levels of autoﬂuorescent storage material in the cortex and thalamus of Cln3Dex7-8 mice, which is reduced by trehalose treatment.
Scale bar, 50mm. All groups of mice, n¼ 3 or 4. (c,d) Confocal images and quantiﬁcation of the amount of storage material in 12-month-old trehalose-
treated and control mice in the primary somatosensory cortex (S1BF; c) and in the interconnected thalamic relay nucleus (VPM/VPL; d). Thresholding
image analysis revealed higher levels of autoﬂuorescent storage material in the cortex and thalamus of Cln3Dex7-8 mice, which is partially rescued by
trehalose treatment. All groups of mice, n¼ 3 or 4. Scale bar, 50mm (a–d). Data represent means±s.e.m. *Po0.05, **Po0.01, ***Po0.001. (e,f) TEM
analysis of untreated (UT) Cln3Dex7-8 mouse brains show marked accumulation of electron-dense cytoplasmic material (yellow arrowheads) in both
Purkinje cells (e) and cortical neurons (f). Frequency distribution of FPPs counting revealed a signiﬁcant reduction of FPPs in trehalose (Tre)-treated mice. n
of cells per group of mice¼ 18. Kolmogorov–Smirnov test was applied for frequency analysis. Scale bars, 2 mm.
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primary cells in normal and pathological conditions. We
performed real-time quantitative PCR (qPCR) using messenger
RNAs extracted from patient-derived JNCL ﬁbroblasts and
control ﬁbroblasts following trehalose administration in culture
media. The results showed increased expression of tested CLEAR
genes in treated versus untreated ﬁbroblasts with either genetic
background (Fig. 5a,b). We next performed microarray expres-
sion analysis of JNCL and control ﬁbroblasts following trehalose
treatment. Gene ontology analysis of genes with at least a twofold
change in expression levels compared with untreated controls
showed that the only over-represented class of genes was that
related to lysosomal metabolism in both JNCL and control
ﬁbroblasts (fold enrichment45 and Po10 10 for both analyses).
Co-regulation analysis8,9 revealed that CLEAR genes are at the
center of the network of genes induced by trehalose (Fig. 5c),
suggesting that TFEB activation may be the ﬁrst transcriptional
response of the cell on trehalose administration. Gene set
enrichment analysis (GSEA) of expression changes in control
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ﬁbroblasts conﬁrmed that the vast majority of lysosomal genes
were upregulated on trehalose administration (enrichment score,
ES¼ 0.67, Po0.0001; Fig. 5d). GSEA of TFEB direct targets
with a known role in lysosomal metabolism showed an even
greater enrichment (ES¼ 0.82, Po0.0001; Fig. 5e), indicating
that trehalose speciﬁcally activates TFEB-mediated lysosomal
regulation. GSEA of gene expression changes in JNCL ﬁbroblasts
yielded similar outcomes (Fig. 5f,g); CLN3 deﬁciency therefore
does not disrupt TFEB-mediated lysosomal enhancement.
We conﬁrmed that TFEB activation induces the CLEAR
network in primary cortical neuron cultures from WT and
Cln3Dex7-8 mice by real-time qPCR (Fig. 6a,b). Immunoblot of
proteins extracted from primary cortical astrocyte cultures
from WT and Cln3Dex7-8 mice showed increased LAMP1 levels
(a marker of lysosomes) on trehalose administration
(Supplementary Fig. 7), conﬁrming lysosomal expansion in glial
cells. Confocal microscopy of mouse brain sections and
expression analysis of whole brain homogenates from WT and
Cln3Dex7-8 mice by real-time qPCR showed that oral trehalose
administration resulted in TFEB nuclear translocation (Fig. 6c,d)
and upregulation of lysosomal and autophagy genes (Fig. 6e,f).
TFEB and the CLEAR network are therefore activated in vivo.
Akt controls TFEB activity via phosphorylation at S467.
Our data indicate that a pharmacologically actionable pathway
activates TFEB and enhances cellular clearance, independent of
mTORC1. In the eukaryotic cell, regulatory pathways tend to be
based on redundant, dynamically stratiﬁed signalling networks
that maximize output effectiveness while preserving adaptability
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to ever-changing cell conditions42,43. Thus, we reasoned that
upstream regulators of TFEB might lie in the same signalling
cascade that includes mTORC1. The kinase activity of mTORC1
is tightly regulated by TSC2, which becomes inactive on
phosphorylation by the PI3K/Akt signalling pathway44. Because
inhibition of either PI3K or Akt resulted in TFEB nuclear
translocation similar to mTORC1 inhibition by Torin 1
(Fig. 7a,b), we investigated whether Akt directly regulates TFEB
activity independent of mTORC1. We used Tsc2 / cells to test
TFEB responsiveness to Akt activity under conditions of
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constitutive activation of mTORC1. Consistent with previous
studies44, Akt activity could be stimulated by serum repletion in
Tsc2 / cells, where the mTORC1 pathway is insensitive to
serum removal or stimulation (Supplementary Fig. 8a).
Importantly, serum re-stimulation of serum-starved Tsc2 /
cells resulted in TFEB nucleus-to-cytosol translocation, which
was prevented by preincubation with the Akt inhibitor MK2206
(Supplementary Fig. 8b). Thus, Akt activity is required for TFEB
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Figure 5 | Activation of the CLEAR network by trehalose. (a,b) Expression analysis of control (CTRL; a) and JNCL ﬁbroblasts (b) showing upregulation of
lysosomal genes on trehalose treatment. Gene expression was normalized relative to the housekeeping gene, GAPDH. (c) Cytoscape-generated network
representing genes upregulated by trehalose administration. Dots (representing genes) are connected by blue lines with colour intensity proportional to the
extent of co-regulation. The network has a core of genes with tighter expression relationships containing TFEB lysosomal targets (center of network), while
other genes more loosely correlated are found in the periphery of the network. (d,e) GSEA of transcriptome changes following trehalose administration to
CTRL (d) and JNCL ﬁbroblasts (e), with lysosomal genes. Upper panels show the enrichment plots generated by GSEA of ranked gene expression data (left,
red: upregulated; right, blue: downregulated). Vertical blue bars indicate the position of genes in each selected gene set within the ranked lists. Lower panels
show the cumulative distribution of lysosomal genes within the ranked lists. The ranking positions that include 50% of analysed genes are indicated. The
analysis shows enrichment of lysosomal genes among genes that were upregulated following trehalose administration. (f,g) GSEA of transcriptome
changes following trehalose administration to CTRL (f) and JNCL ﬁbroblasts (g), with lysosomal genes and TFEB targets with a known role in lysosomal
metabolism being reported. TFEB lysosomal targets have a higher ES score than general lysosomal genes, indicating that trehalose preferentially
upregulated TFEB targets participating in lysosomal function in both control and JNCL ﬁbroblasts. Data represent means±s.e.m.
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cytosolic localization on serum stimulation independent of
mTORC1. We also checked possible interdependence with
GSK3b, another factor modulating TFEB subcellular
localization45–47. An immunoblot analysis showed no detectable
effect of trehalose on GSK3b activity (Supplementary Fig. 9a),
and confocal microscopic analyses showed that both trehalose
and MK2206 were able to induce nuclear translocation of TFEB
in cells expressing constitutively active GSK3b (CA-GSK3b/S9A-
GSK3b; Supplementary Fig. 9b). In a reciprocal experiment, the
GSK3b inhibitor CHIR-99021 promoted nuclear translocation of
TFEB in cells expressing constitutively active Akt (Akt308D/473D
or Akt-DD)48 (Supplementary Fig. 9c). Thus, these results
indicate that Akt and GSK3b regulate TFEB independently. We
also veriﬁed that trehalose does not inhibit the extracellular signal
-regulated kinase (ERK), a previously reported modiﬁer of TFEB
activity10 (Supplementary Fig. 10).
To determine whether Akt directly phosphorylates TFEB,
we ﬁrst built a position weight matrix (PWM) of Akt target
sequences by using experimentally validated Akt substrates, and
used Akt PWM to scan TFEB amino-acid sequences from
multiple species. This analysis identiﬁed S467 as a conserved
candidate phosphoacceptor motif for Akt (Fig. 7c). A mutant
form of TFEB (S467A) shifted to a lower molecular weight when
analysed by western blot (Supplementary Fig. 11) and displayed
reduced cytosolic localization and increased dual nuclear-
cytosolic distribution (Fig. 7d) similar to mutants for mTORC1
target sites (Supplementary Fig. 12). Importantly, TFEB(S467A)
showed increased ability to induce the expression of TFEB target
genes compared to WT TFEB (Fig. 7e). Cytosolic TFEB has been
shown to interact with the 14-3-3 proteins18,19. As expected,
TFEB(S467A) showed diminished co-localization and interaction
with the 14-3-3 proteins likely due to its increased nuclear
localization (Fig. 7f,g). TFEB(S467A) also displayed nuclear
localization in cells with constitutively active mTORC1
(Supplementary Fig. 13).
An in vitro Akt kinase assay showed that Akt phosphorylates
puriﬁed TFEB, but not the S467A mutant form of TFEB (Fig. 7h).
Therefore, these results identify TFEB as a direct phosphorylation
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substrate of Akt and demonstrate that S467 is a key residue for
such phosphorylation. Transfection of bicistronic TFEB-Flag–
internal ribosomal entry site (IRES)–green ﬂuorescent protein
(GFP) and TFEB(S467A)-Flag–IRES–GFP vectors showed that
the mutant TFEB protein was more stable than WT TFEB
(Supplementary Fig. 14), thus indicating that Akt also regulates
TFEB stability. AKT knockdown enhanced TFEB nuclear
translocation and increased LAMP1 expression (Fig. 7i), thus
conﬁrming that Akt negatively regulates TFEB activity. Impor-
tantly, trehalose inhibited Akt activity while increasing autopha-
gic ﬂux (Fig. 7j), and expression of constitutively active Akt (Akt-
DD) abolished the effect of trehalose on TFEB nuclear
translocation (Fig. 7k). These experiments demonstrate mechan-
istically that Akt inhibition mediates trehalose activation of TFEB.
Trehalose-mediated Akt inhibition was conﬁrmed in the brain of
trehalose-treated mice (Fig. 7l). Co-immunoprecipitation (IP)
experiments conﬁrmed that Akt interacts with TFEB
(Supplementary Fig. 15a) and that such interaction does not
substantially change when using the S467A mutant version of
TFEB (Supplementary Fig. 15b), suggesting that trehalose affects
the activity of Akt rather than its interaction with TFEB. We also
tested whether TFEB paralogues, MITF and TFE3, are responsive
to Akt activity. Confocal microscopic analysis of HeLa cells
transfected with MITF and TFE3 constructs showed that
inhibition of Akt with MK2206 promoted nuclear translocation
of these two factors (Supplementary Fig. 16), thus suggesting
possible conservation of this regulatory mechanism.
Akt is the subject of intensive clinical investigation due to its
involvement in cancer. Among Akt modulators, MK2206 is a
potent Akt oral inhibitor that is currently in pre-clinical and
phase I clinical studies49,50. Similar to trehalose, administration of
MK2206 to HeLa cells resulted in increased number of LC3
puncta (Fig. 8a), increased LC3-II protein levels (Fig. 8b), and
increased number of autophagic vesicles as observed by TEM
(Fig. 8c), indicating that MK2206 activates autophagy. In
addition, MK2206 treatment also upregulated the expression of
lysosomal and autophagy genes (Fig. 8d). Intraperitoneal
injection of MK2206 led to inhibition of Akt activity (Fig. 8e)
and resulted in TFEB nuclear translocation (Fig. 8f) in the mouse
brain, which in turn promoted upregulation of lysosomal and
autophagy genes as detected by expression analysis of whole
brain homogenates (Fig. 8g). Together, these data provide
evidence that pharmacological inhibition of Akt enhances the
autophagic-lysosome pathway in vitro and in vivo.
We ﬁnally tested whether MK2206 modulates cellular
clearance using accumulation of ceroid lipopigment as a direct
readout. Inhibition of Akt by MK2206 in JNCL ﬁbroblasts indeed
resulted in clearance of ceroid lipopigment similar to that
observed with trehalose treatment (Fig. 9a), which was reversed
by withdrawal of MK2206 or trehalose (Supplementary Fig. 17).
We then used cell lines with mutations in other lysosomal genes
to test whether Akt inhibition enhances cellular clearance
independently of the molecular pathways whose dysfunction
leads to the buildup of aberrant intralysosomal storage. We ﬁrst
tested a cell line-bearing mutations in the gene encoding
palmitoyl-protein thioesterase-1 (PPT1), an enzyme involved in
protein degradation whose deﬁciency results in intralysosomal
storage of palmitoylated proteins and neurodegeneration
(OMIM #600722). Previous work has shown that chemical
cleavage of thioester linkage in palmitoylated proteins results in
neuroprotection in a mouse model of PPT1 deﬁciency,
thus directly linking the accumulation of undegraded proteins
to disease pathogenesis51. Inhibition of Akt using MK2206
dramatically decreased the intralysosomal protein buildup in
patient-derived primary ﬁbroblasts bearing mutations in PPT1
(Fig. 9b). Similarly, MK2206 administration decreased protein
buildup in primary ﬁbroblasts with defective tripeptidyl
peptidase I (TPP1; Fig. 9c), an exopeptidase that sequentially
removes tripeptides from the N termini of proteins and whose
deﬁciency causes neurodegeneration (OMIM #607998). Finally,
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Figure 9 | Pharmacological inhibition of Akt enhances cellular clearance in patient-derived cells. (a–d) Confocal microscopy analysis of primary
ﬁbroblasts with defective CLN3 (c.461-677del; a), PPT1 (c.665T4C, p.L222P; b), TPP1 (c.380G4A, p.R127Q; g.3556, IVS5-1G4C; c) or MFSD8
(c.103C4T, p.R35X; d) shows that MK2206 and trehalose induce clearance of ceroid lipopigment deposits (green). Defective proteins are indicated. More
than 60 cells have been analysed for each panel. Scale bar, 30 mm. (e) Schematic diagram for Akt-dependent trehalose activation of TFEB. Data represent
means±s.e.m. *Po0.05, **Po0.01, ***Po0.001.
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we tested a model of intralysosomal storage caused by the
deﬁciency of the transmembrane transporter, MFSD8 (OMIM
#611124). While the molecular pathway linking MFSD8 function
to buildup of proteinaceous material is currently unknown,
such aberrant storage is associated with neurodegeneration. Akt
inhibition with MK2206 resulted in markedly enhanced cellular
clearance in primary ﬁbroblasts defective for MFSD8 (Fig. 9d).
Together, these data demonstrate that Akt inhibition can enhance
cellular clearance downstream and independent of the primary
disrupted pathway. On the basis of on our results, we propose
that the Akt-TFEB signalling pathway (schematized in Fig. 9e)
may be leveraged with small molecules to improve clearance of
toxic material in neurodegenerative diseases.
Discussion
This study identiﬁes Akt control of TFEB activity as an
mTORC1-independent, pharmacologically actionable target with
potential relevance for the treatment of neurodegenerative storage
diseases. TFEB is indeed a central hub controlling lysosome-based
cellular clearance8, whose potential therapeutic relevance has
been demonstrated in models of the major neurodegenerative
diseases, including Alzheimer’s disease, Parkinson’s disease and
Huntington’s disease through proof-of-principle studies based on
heterologous expression of TFEB8,13–17. Our data using Batten
disease mice as an in vivo model of neuronal intralysosomal
storage demonstrate that lysosomal enhancement can be
leveraged to counteract defects in clearance pathways due to
primary impairment of lysosomal homoeostasis and function.
These ﬁndings are relevant for lysosomal storage disorders that,
like the juvenile form of Batten disease, are caused by the
deﬁciency of a membrane-bound protein for which approaches
based on bone marrow transplantation or gene therapy are
inherently difﬁcult to apply52. More broadly, our ﬁndings are of
potential interest for neurodegenerative storage diseases for which
validated targets of treatment have still not been established, yet
experimental evidence has identiﬁed enhancement of cellular
clearance pathways as a candidate therapeutic target. Pioneering
genetic and mechanistic studies have indeed unveiled strong links
between pathogenic mechanisms and lysosomal function in these
diseases2–6.
Understanding how to pharmacologically control TFEB
activity is urgently needed to move the ﬁeld forward and help
set-up clinical studies to evaluate the efﬁcacy of TFEB-mediated
lysosomal enhancement in neurodegenerative disease. Recent
cell-based studies have shown that TFEB activity may be
regulated by mTORC1-mediated phosphorylation at speciﬁc
serine residues in response to changes in the nutritional
status18–20. This represented a signiﬁcant discovery because
mTORC1 itself is known to be involved in the regulation of
autophagy and has therefore been the subject of pre-clinical
investigation in models of neurodegenerative diseases. Results
from multiple studies indicated that autophagy upregulation via
mTORC1 inhibition attenuates neurodegenerative pathology in
mouse models of Huntington’s disease53, Alzheimer’s disease54,55,
tauopathy56, frontotemporal lobar dementia57, spinocerebellar
ataxia type III (ref. 58) and familial prion disease59. mTORC1,
however, acts as a central regulatory hub controlling anabolic
pathways such as cell growth by modulating the synthesis of
proteins, lipids and nucleotides60, and long-term mTORC1
inhibition results in induction of immunosuppression and
impaired wound healing3,61. Clinically, mTORC1 inhibition is
obtained by using rapamycin, the ﬁrst identiﬁed mTORC1
allosteric inhibitor62, or rapamycin analogues that present
improved pharmacological proﬁles. However, allosteric inhibition
of mTORC1 by rapamycin has small or no effects on TFEB
activation18–20. Our identiﬁcation of an mTORC1-independent
route to pharmacologically activate TFEB offers a new avenue to test
TFEB-mediated enhancement of cellular clearance in
neurodegenerative diseases. Intriguingly, TFEB pharmacological
activation and mTORC1 allosteric inhibition could be used as
orthogonal, synergic activators of autophagic–lysosomal clearance
pathways, ideally identifying drug dosages that would minimize
potential side effects of either drug. The increased availability of Akt
inhibitors and, importantly, of dual PI3K/mTOR inhibitors may
therefore prove beneﬁcial for future pre-clinical and clinical studies.
Akt, a member of the AGC serine/threonine kinase family,
plays key roles in the cell survival and apoptosis inhibition.
Abnormal activation of Akt may occur through mechanisms such
as Akt mutation or dysregulation of upstream signalling
pathways, and is an important driver of malignant progression
and chemoresistance63. This makes Akt a potential therapeutic
target for cancer treatments. Intense pre-clinical and clinical
effort is indeed being placed on characterizing downstream
pathways regulated by Akt and in testing chemical inhibition of
Akt in cancer patients49,50,64,65. Interestingly, pioneering studies
have shown that Akt regulates macroautophagy66 and chaperone-
mediated autophagy67. While it remains to be determined how a
disaccharide like trehalose modulates Akt activation, the ﬁnding
that Akt regulates lysosomal function via TFEB adds a crucial
layer in the characterization of Akt’s role in autophagic–
lysosomal clearance pathways and offers a novel angle in
understanding the cellular processes that are impacted by the
clinical use of Akt inhibitors. Since PI3K-Akt pathway plays a key
role in the integration of signals from secreted growth factors to
stimulate mTORC1 activity, it is also interesting that Akt
inhibition by trehalose does not inhibit mTORC1. In response
to growth factors, Akt phosphorylates and inhibits the TSC2,
which acts as a negative regulator of mTORC1 by maintaining the
mTORC1 direct activator, Rheb, in its inactive GDP-bound
state68. Another upstream regulator of mTORC1 that acts in
parallel to Akt via the same TSC2/Rheb cascade is ERK, which
integrates signals from growth factors through the Ras-ERK
pathway. Similar to Akt, ERK also inhibits TSC2. We found that
trehalose inhibits Akt but not ERK activity; therefore, it is
possible that active ERK is sufﬁcient to keep TSC2 inactive, thus
resulting in an unmodiﬁed mTORC1 signalling. TSC proteins
also integrate signals from other pathways, thus additional layers
of regulation might be responsible for mTORC1 insensitivity to
trehalose.
In summary, the identiﬁcation of Akt as an mTORC1-
independent regulator of TFEB opens new perspectives for the
pharmacological control of TFEB-mediated cellular clearance.
Akt modulation of TFEB might be exploited therapeutically to
enhance cellular clearance in neurodegenerative storage disorders,
and the availability of drugs that target the Akt-TFEB signalling
pathway warrants future studies aimed at the clinical translation
of TFEB-mediated lysosomal enhancement in neurodegenerative
diseases.
Methods
Cell culture and treatment. Control (Coriell Institute, USA) and JNCL ﬁbroblasts
(Gaslini Institute, Italy) were grown in DMEM (1:1, HyClone) supplemented
with 10% heat-inactivated fetal bovine serum (FBS, Atlanta Biologicals), 2mM
L-glutamine, 100Uml 1 penicillin and 100mgml 1 streptomycin (Invitrogen).
HeLa cells were incubated for 2 h with LY294002 (50mM, Cell Signaling), Torin 1
(300 nM, Cayman Chemical) or for 24 h with trehalose (100mM, Sigma),
rapamycin (300 nM, Sigma), MK2206 (1mM, Selleckchem), U0126 (10 mM, Tocris)
and dialyzed serum (GE Healthcare Life Sciences) for 30min.
Cortical and hippocampal neuron cultures. Cortical and hippocampal neurons
were prepared from E17.5 and postnatal day 0–1 mice and plated on poly-D-lysine
coated six-well plates (BD Biosciences) in Neurobasal medium supplemented with
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GlutaMAX-I (Invitrogen), B-27 and 1% FBS. At days in vitro 4, neurons were
treated with 100mM trehalose. At days in vitro 8, neurons were collected and RNA
extraction was performed.
Cortical astrocytes culture. Astrocytes were isolated from P0-1 mice and plated
on poly-D-lysine coated six-well plates (BD Biosciences) in the presence of DMEM
high glucose, supplemented with 10% FBS and 100Uml 1 penicillin and
100mgml 1 streptomycin. After 7 days, the glial cell layer was removed and
astrocytes were plated for treatment. An amount of 100mM of trehalose was
dissolved in the media the day after and kept for 4 days. Finally, astrocytes were
collected and protein extracts were analysed by western blot assay.
Immunoﬂuorescence assay. For immunoﬂuorescence assay, cells were grown on
coverslips in 24-well plates. After the treatment, cells were washed with PBS and
ﬁxed with methanol for 10min. Cells were then blocked with blocking reagent
(0.1% saponin, 10% bovine serum in PBS) for 1 h and incubated with appropriate
primary antibody(s) (1:100) for 3 h at room temperature. After three washes with
PBS, the cells were incubated with appropriate secondary antibodies (1:500) for 1 h
at room temperature. Coverslips were then mounted with vectashield containing
4,6-diamidino-2-phenylindole (H-1200) for imaging via confocal microscopy.
Western blot. Brain tissue and cultured cells were collected and lysed in RIPA
buffer (50mM Tris-HCl, ph 7.4, 1% NP40, 0.5% Na-deoxycholate, 0.1% SDS,
150mM NaCl, 2mM EDTA and 50mM NaF) including a cocktail of protease
(Roche) and phosphatase (SIGMA) inhibitors. Protein concentrations were
measured with the bicinchoninic acid protein assay kit (Pierce, Rockford, IL), using
bovine serum albumin as standard. Lysates were separated via SDS–polyacrylamide
gel electrophoresis (PAGE) and then transferred to nitrocellulose membranes. Blots
were incubated in blocking buffer (5%, w/v, dried skimmed milk in Tris-buffered
saline, pH 7.4 and 0.2% Tween 20, TBST) followed by overnight incubation with
appropriate antibodies diluted in blocking buffer (5% dry milk). Western blot
images were acquired by LAS 4000 (GE Healthcare) and quantiﬁed using ImageJ.
Images have been cropped for presentation. Full size images are presented in
Supplementary Fig. 18.
Antibodies. Antibodies to Akt (#9272, 1:1,000), phospho-Akt(S473) (#4060,
1:500), phospho-Akt(T308) (#13038, 1:500), p70 S6K (#9202, 1:1,000),
phospho-P70 S6K(T389) (#9205, 1:500), 4E-BP1 (#39452, 1:1,000), phospho-4E-
BP1(T37/46) (#9459, 1:500), S6 ribosomal protein (#2217, 1:1,000), phospho-S6
ribosomal protein(S240/244) (#2214, 1:1,000), LAMP1 (#3243, 1:1,000), Histone
3 (#4469, 1:1,000), Phospho-(Ser) 14-3-3 Binding Motif (#9601S, 1:500), Rictor
(#2114, 1:500), Raptor (#2280, 1:500), ERK1/2 (#9102, 1:1,000), phosphor-ERK1/2
(#9101, 1:1,000), GSK-3b (D5C5Z) XP (#12456S, 1:1,000), phospho-GSK-3b (Ser9)
(#9336S, 1:500), GFP (D5.1) (#29556, 1:1,000) and human TFEB (#4240, 1:500)
were purchased from Cell Signaling. Antibody to GAPDH (#32233, 1:1,000) was
purchased from Santa Cruz. Antibody to glial ﬁbrillary acidic protein (GFAP) was
purchased from DAKO (#Z0334, 1:1,000). Antibody to CD68 was purchased from
AbD Serotec (#MCA1957, 1:1,000). Antibody to mouse TFEB was purchased from
Proteintech (#13372-1-AP, 1:500). Mouse anti-FLAG M2 (#F1804, 1:1,000) and
rabbit anti-FLAG (#F7425, 1:1,000) antibodies were purchased from Sigma. Pan
14-3-3 antibody (K-19) (#SC629, 1:300) was purchased from Santa Cruz. Antibody
to TSC2 was purchased from Abcam (#32554, 1:1,000).
Cytosolic and nuclear protein fractionation. Cell pellets were resuspended in
lysis buffer (10mM Hepes pH 7.9, 10mM KCl, 0.1mM EDTA and 0.4% Nonidet
P40) with inhibitors by pipetting and kept in ice for 30min. After 1min of spin at
full speed, the supernatant was collected as cytosolic fraction. The pellet was
washed twice with lysis buffer and resuspended with nuclear buffer (20mM Hepes
pH 7.9, 0.4M NaCl and 1mM EDTA) containing phosphatases and proteases
inhibitors. After 15min of vigorous shaking on an Eppendorf shaker, the pellet was
spun down at full speed for 10min. The supernatant was used as the nuclear
fraction.
In vitro kinase assay. An in vitro kinase assay was performed using puriﬁed,
active AKT1 enzyme (SignalChem, Richmond, Canada). Whole cell lysates for IP
were prepared in IP lysis buffer (20mM Tris, pH 7.5, 150mM NaCl, 1mM EDTA
and 1% Triton X-100) containing protease inhibitors and 1mM Na3V04. Cell
lysates (1,000 mg) were incubated overnight at 4 C with 10 mg of either mouse
anti-FLAG antibody or mouse IgG (Sigma-Aldrich, St. Louis, MO) crosslinked to
protein A/G beads (Pierce Crosslink IP Kit, Life Technologies, Grand Island, NY),
made up to 300ml total volume with IP lysis buffer. The immune complexes were
collected by centrifugation, washed ﬁve times in IP lysis buffer and eluted with
10ml of 3X FLAG peptide. The eluant was diluted to 30 ml with 1 kinase buffer
(25mM Tris, pH 7.5, 5mM b-glycerolphosphate, 10 mM ATP, 2mM dithiothreitol,
0.1mM Na3VO4 and 10mM MgCl2). Kinase reactions were initiated by adding
200 ng of AKT1 and 0.5 mCi [g-32P]ATP (3,000 Cimmol 1, PerkinElmer Life
Sciences) in 20 ml of kinase buffer. The reactions were stopped after a 15-min
incubation at 30 C by adding SDS–PAGE loading buffer and heating to 95 C for
10min. The samples were resolved on a 4–12% SDS–PAGE gel and analysed by
autoradiography. TFEB-S467A-3xFlag was generated by using the QuikChange
XLII site-directed mutagenesis kit (Agilent) and the following oligos: 50-AGCAGC
CGCCGGAGCGCCTTCAGCATGGAGGAG-30, 5-CTCCTCCATGCTGAAGGC
GCTCCGGCGGCTGCT-30 , according to the manufacturer’s directions.
Quantitative real-time PCR. Total RNA was extracted from the control and JNCL
ﬁbroblasts and from WT and Cln3Dex7-8 cortical neuron cultures using the RNEasy
kit (Qiagen) according to the manufacturer’s instructions. Half of the mouse
brain was processed for the RNA extraction and one microgram was used for
complementary DNA synthesis by QuantiTect Reverse Transcription kit (Qiagen).
The primers for PCR with reverse transcription reactions are listed in
Supplementary Table 1. Quantitative real-time PCR was performed by using iQ
SYBR Green Supermix on the CFX96 Touch Real-Time Detection System (Bio-Rad
Laboratories). Samples were heated for 3min at 95 C and ampliﬁed in 39 cycles for
11 s at 95 C, 45 s at 60 C with last cycle of 10 s at 95 C, 5 s at 65 C and 5 s at
95 C. Analyses were conducted using CFX manager software (Bio-Rad) and the
threshold cycle (CT) was extracted from the PCR ampliﬁcation plot. Relative gene
expression was determined using the DDCT method, normalizing to GAPDH
(for human genes) and cyclophilin (for mouse genes). The change in messenger
RNA level of the genes was expressed in fold change as previously described8.
Error bars represent s.e.m. *Po0.05, **Po0.01, ***Po0.001.
RNA interference. For siRNA knockdown, cells were transfected using
Lipofectamine RNAiMAX transfection reagent (Invitrogen) with Stealth RNAi
Negative Control Duplex (Thermo-Scientiﬁc 12935-300) or with Stealth siRNAs
duplex targeted against AKT1 (Thermo Scientiﬁc, HSS176614, HSS100346 and
HSS100345). siRNA against Rictor was purchased from Cell Signaling (8622).
Cells were analysed 72 h after transfection.
Microarray experiments. Total RNA from control and JNCL ﬁbroblasts with and
without trehalose treatment (100mM, 4 days) was used to prepare complementary
DNA for hybridization to the Illumina Human HT-12 V4.0 array platform.
Experiments were performed in triplicate. Expression analysis was performed at the
Microarray Core and Cell and Regulatory Biology, University of Texas, Houston,
TX, USA. A Po0.01 was used as a threshold for signiﬁcance for assessing
differential gene expression. GSEA was performed as previously described10,11.
The cumulative distribution function was constructed by performing 1,000 random
gene set membership assignments. A nominal Po0.01 and an a false discovery rate
(FDR)o10% were used as thresholds for signiﬁcance of the ES. Gene ontology
analysis was performed with the web tool DAVID (https://david.ncifcrf.gov/) using
default parameters. Pathway co-expression analyses were performed as previously
described8,9, and Cytoscape was used to represent graphically the expression
correlation data.
Animal husbandry. Cln3Dex7-8 mice (stock no. 004685; Cln3tm1.1Mem/J; CD-1
background)32 were obtained from the Jackson Laboratory. Control (CD-1) and
Cln3Dex7-8 mice were housed 3–4 per cage in a room with a 12-h light/12-h dark
cycle. Food and water were provided ad libitum. All mice used in this study were
analysed at 8 and 12 months of age and were littermates produced by crossing
heterozygous Cln3Dex7-8 mice. Only males were used for this analysis. Investigators
were blinded when analysing the data, and no randomization was necessary.
No data were excluded from this study.
Intraperitoneal injection. Mice were injected intraperitoneally with MK2206
(120mg kg 1) for four times every other day. MK2206 was formulated in 30%
captisol in water. Four Cln3Dex7-8 mice were injected with MK2206 and four were
injected with 30% captisol as vehicle control.
Trehalose treatment. Trehalose (Swanson) was dissolved in drinking water to a
ﬁnal concentration of 2% and changed twice a week. Trehalose-containing water
was given to Cln3Dex7-8 and WT mice by spontaneous oral administration starting
at 21 days of age and continuing until the day the mice died naturally (life span
assessment) or were sacriﬁced for other studies.
Immunohistochemistry. Eight- and 12-month-old homozygous Cln3Dex7-8 mice
and age-matched controls were anaesthetized with isoﬂurane and transcardially
perfused with PBS followed by 4% buffered paraformaldehyde in 0.1M sodium
phosphate buffer, pH 7.4. Brains were subsequently removed and postﬁxed
overnight. Before sectioning, the brains were cryoprotected in a solution containing
30% sucrose in Tris-buffered saline (TBS: 50mM Tris, pH 7.6). Consecutive 40 mm
ﬂoating coronal sections were collected in 96-well plates. Series of sections were
then stained with primary antisera against CD68 or GFAP, followed by either
rabbit anti-rat (VectorLab) and swine anti-rabbit (DAKO) secondary antibodies,
and immunoreactivity detected with Vectastain ABC (avidin-biotin) kit (Vector)
and diaminobenzidine as a chromogen.
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Quantitative analysis of glial phenotype. Thirty non-overlapping images were
captured, on three consecutive sections, through each region of interest. All RGB
images were captured via a live video camera (JVC, 3CCD, KY-F55B), mounted
onto a Zeiss Axioplan microscope using a  40 objective and saved as JPEGs. All
parameters including lamp intensity, video camera set-up and calibration were
maintained constant throughout image capturing. Images were subsequently
analysed using ImageJ analysis software (NIH), using an appropriate threshold that
selected the foreground immunoreactivity above background. This threshold was
then applied as a constant to all subsequent images analysed per batch of animals
and reagent used to determine the speciﬁc area of immunoreactivity for each
antigen in each region. This analysis was performed blind to genotype. Data
were plotted graphically as the mean percentage area of immunoreactivity per
ﬁeld±s.e.m. for each region.
Storage burden. To analyse the relative level of the autoﬂuorescent storage
material present in each brain region, mouse brain sections spanning the S1BF and
VPM/VPL were mounted onto gelatin-chrome-coated slides and cover-slipped
with Vectashield (Vector Laboratories, Peterborough, UK). Non-overlapping
images from each section were captured at  63 magniﬁcation using a Leica
SP5 confocal microscope and a 488 nm excitation laser (Leica Microsystem).
Thresholding image analysis was performed to determine the storage burden
present in each region. During image capture, all laser parameters and calibrations
were kept constant. Semiquantitative thresholding image analysis was carried out
using ImageJ (NIH).
TEM. Mice were anaesthetized and perfused intracardially with saline solution
followed by 2% formaldehydeþ 2.5% glutaraldehyde in 0.1M sodium cacodylate
buffer (pH 7.4). Brains were removed and small pieces of cerebellum and cortex
were collected, and further postﬁxed in 2% formaldehydeþ 2.5% glutaraldehyde,
0.1M sodium cacodylate buffer (pH 7.4) for 24 h. One-hundred micrometre
coronal sections were cut with a vibratome and ﬁxed in 1% OsO4 in 0.1M
cacodylate for 1 h, stained with uranyl acetate dehydrated and embedded in
Eponate 812. Ultrathin sections at 60 nm were obtained on an RMC MT6000
ultramicrotome and examined with a Hitachi H7500 transmission electron
microscope. Images were captured using a Gatan US1000 high-resolution digital
camera and Digital Micrograph software (v1.82.366).
Tissue preparation for MRI. Mice were transcardially perfused before imaging.
The head was removed and then the skin, muscle, ears, nose tip and lower jaw were
removed to expose the skull. The head was ﬁxed overnight in 4% paraformaldehyde
at 4 C. The head was then transferred to 40mLs of 0.01% sodium azide in PBS
and rocked for 7 days at 4 C. The head was transferred to a solution of 5mM
gadopentetate dimeglumine (Bayer HealthCare Pharmaceuticals Inc., Wayne, NJ)
and 0.01% sodium azide in PBS and rocked for 25–35 days at 4 C. Incubation with
gadopentetate dimeglumine improved the signal-to-noise ratio. Before imaging, the
head was equilibrated to room temperature for 6–8 h.
Magnetic resonance protocol. A total of 48 scans per mouse were acquired on a
9.4 T Bruker Avance Biospec Spectrometer, 21-cm bore horizontal scanner with
35mm volume resonator (Bruker BioSpin, Billerica, MA) with Paravision 5.0
software (Bruker Biospin, Billerica, MA). The three-dimensional diffusion tensor
imaging (DTI) scan parameters are as follows: spin echo, b-value¼ 0 and
1,000 smm 2, 20 diffusion directions with one non-diffusion weighted image,
repetition time (TR)¼ 500ms, echo time (TE)¼ 14.8ms, ﬁeld of view
(FOV)¼ 1.7 1.2 2.4 cm or 2.0 1.4 3.2 cm, matrix¼ 128 96 96, number
of excitations (NEX)¼ 1, d¼ 3ms, D¼ 7ms. The acquisition time was B15 h.
MRI image processing. The MRI images were ﬁrst processed on DTI studio to
extrapolate the fractional anisotropy. Subsequently, the Amira software (Visage
Imaging, Inc., San Diego, CA) was used to deﬁne the ROI of the CC and to
calculate the volume for each mouse. Volumetric measurements of the CC were
performed in a blinded manner.
ABR measurements. ABRs were measured as previously described69. Brieﬂy,
10-month-old mice (n¼ 4–6 per genotype/treatment group) were anaesthetized
using an intraperitoneal injection of ketamine (100mg kg 1) and xylazine
(10mg kg 1) and then immobilized in a head holder. Normal body temperature
was maintained throughout the procedure by placing the mice on a heating pad.
Pure tone stimuli from 4 to 48 kHz were generated using Tucker-Davis
Technologies System 3 digital signal processing hardware and software
(Tucker-Davis Technologies, Alachua, FL, USA), and the intensity of the tone
stimuli was calibrated using a type 4,938 1/400 pressure-ﬁeld calibration
microphone (Bruel and Kjar, Nærum, Denmark). Response signals were recorded
with subcutaneous needle electrodes inserted at the vertex of the scalp, the
postauricular region and the back leg (ground)69. Auditory thresholds were
determined by decreasing the sound intensity of each stimulus from 90 to 10 dB in
5 dB steps, until the lowest sound intensity with reproducible and recognizable
waves in the response was reached. Mean hearing thresholds±s.d. (dB sound
pressure level (SPL)) were plotted as a function of stimulus frequency (kHz).
Statistical analysis consisted of one-way analyses of variance to reveal overall trends
accompanied by two-tailed Student’s t-tests at individual frequencies to evaluate
frequency-speciﬁc effects. T-test P values were adjusted for multiple comparisons
using the Holm method. R (version 2.13) was used for all statistical analyses.
Akt phosphosite prediction. To identify candidate phosphosites that may be
targeted by Akt, experimentally determined, non-redundant Akt phosphosite
sequences were downloaded from PhosphositePlus website (http://www.
phosphosite.org/) and used to build a PWM to scan TFEB amino-acid sequence
using the MEME Suite 4.11.0 (http://meme-suite.org/). TFEB sequences were
aligned by using MultAlin (http://multalin.toulouse.inra.fr/) with default
parameters.
Statistics. The results are presented as the means±s.e.m. Statistical signiﬁcance of
mean differences for each parameter was determined by analysis of variance
for genotype and treatment followed by Tukey’s post hoc test unless otherwise
indicated. A Po0.05 was considered signiﬁcant.
Study approval. All mouse experimental procedures were reviewed and approved
by the Institutional Animal Care and Use Committee at Baylor College of
Medicine.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles. The
Gene Expression Omnibus accession number for gene expression microarray is
GSE76643.
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